Clinical Trial Update: A 48-week Study of the Effect of Dual Therapy (Inhaled Treprostinil and Tadafafil) Versus Monotherapy (Tadalafil). [Phase 4]

View source ↗

Summary

A 48-week Phase 4 trial comparing dual therapy with inhaled treprostinil and tadalafil versus tadalafil alone in pulmonary hypertension has completed and posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Hypertension

Drugs mentioned

• TADALAFIL (TADALAFIL)
• Tyvaso (treprostinil)

Snippet

Sponsor: Stanford University | Conditions: Hypertension, Pulmonary | Phase 4 | Status: COMPLETED | Results posted: 2017-06-02